【中图分类号】R541.7【文献标识码】A【文章编号】1005-2720(2010)05 - 12 - 02
【摘要】目的 观察胺碘酮与维拉帕米治疗阵发性室上速的疗效及安全性。方法 60例阵发性室上速患者随机分为两组,1组给予胺碘酮300mg+0.9% 氯化钠注射液 100ml中静滴,2组给予维拉帕米5～10mg静注。结果 胺碘酮和维拉帕米对阵发性室上速的治疗效果均较好,疗效差异无统计学意义(P>0.05),副作用维拉帕米较胺碘酮高。结论 阵发性室上速应首选维拉帕米,胺碘酮对室上速伴有器质性心脏病疗效较好。
【关键词】胺碘酮;阵发性室上速;维拉帕米。
【Abstract】Objective To observe the treatment of amiodarone and verapamil in paroxysmal supraventricular tachycardia the efficacy and safety.Methods 60 patients with paroxysmal supraventricular tachycardia were randomly divided into two groups, one group was given amiodarone 300mg +0.9% sodium chloride injection in the intravenous infusion of 100 ml. Two group was given intravenous verapamil 5～10mg.ResultsAmiodarone and verapamil for paroxysmal supraventricular tachycardia treatment effects are good,efficacy no statistically significant difference (P>0.05),side-effects of verapamil higher than amiodarone.Conclusion Paroxysmal Supraventricular Tachycardia should be preferred Verapamil,effect of amiodarone on supraventricular tachycardia associated with organic heart disease better effect. ......
百拇医药网 http://www.100md.com/html/paper/1005-2720/2010/05/07.htm
您现在查看是摘要页，全文长 5426 字符。
